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Background: To evaluate the effectiveness and sustainability of self-managed sodium restriction in patients
with chronic kidney disease.
Study Design: Open randomized controlled trial.
Setting & Participants: Patients with moderately decreased kidney function from 4 hospitals in the
Netherlands.
Intervention: Regular care was compared with regular care plus an intervention comprising education,
motivational interviewing, coaching, and self-monitoring of blood pressure (BP) and sodium.
Outcomes: Primary outcomes were sodium excretion and BP after the 3-month intervention and at 6-month
follow-up. Secondary outcomes were protein excretion, kidney function, antihypertensive medication,
self-efficacy, and health-related quality of life (HRQoL).
Results: At baseline, mean sodium excretion rate was 163.66 64.9 (SD) mmol/24 h; mean estimated
glomerular filtration rate was 49.76 25.6 mL/min/1.73 m2; median protein excretion rate was 0.8 (IQR, 0.4-
1.7) g/24 h; and mean 24-hour ambulatory systolic and diastolic BPs were 129 6 15 and 76 6 9 mm Hg,
respectively. Compared to regular care only (n 5 71), at 3 months, the intervention group (n 5 67) showed
reduced sodium excretion rate (mean change, 230.3 [95% CI, 254.7 to 25.9] mmol/24 h), daytime
ambulatory diastolic BP (mean change, 23.4 [95% CI, 26.3 to 20.6] mm Hg), diastolic office BP (mean
change, 25.2 [95% CI, 28.4 to 22.1] mm Hg), protein excretion (mean change, 20.4 [95% CI, 20.7 to
20.1] g/24h), and improved self-efficacy (mean change, 0.5 [95% CI, 0.1 to 0.9]). At 6 months, differences
in sodium excretion rates and ambulatory BPs between the groups were not significant, but differences
were detected in systolic and diastolic office BPs (mean changes of 27.3 [95% CI, 212.7 to 21.9]
and 23.8 [95% CI, 26.9 to 20.6] mm Hg, respectively), protein excretion (mean changes, 20.3 [95% CI,
20.6 to 20.1] g/24h), and self-efficacy (mean change, 0.5 [95% CI, 0.0 to 0.9]). No differences in kidney
function, medication, and HRQoL were observed.
Limitations: Nonblinding, relatively low response rate, and missing data.
Conclusions: Compared to regular care only, this self-management intervention modestly improved
outcomes, although effects on sodium excretion and ambulatory BP diminish over time.
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Box 1. Inclusion and Exclusion Criteria
Inclusion criteria
 Dutch speaking
 $ 18 y
 Being treated by an internist
 Kidney function (eGFR) $ 20 mL/min/1.73 m2
 Protein excretion measurements . 0.2 g/L or 0.3 g/24 h
 2 recent sodiumexcretionmeasurements$ 120 mmol/24 h
 BP . 135/85 mm Hg or controlled BP with the use of
antihypertensive medication, among which at least 1
RAAS blockade
Exclusion criteria
 BP . 180/100 mm Hg or , 125/75 mm Hg
 Received a kidney transplant , 1 y ago
 Diagnosed with type 1 diabetes mellitus
 Had acute kidney failure
 Accelerated kidney function decrease . 6 mL/min/
1.73 m2 in previous year
 Had a cardiovascular event (ie, myocardial infarction or
cerebrovascular event) , 6 mo ago
 Diagnosed with malignancy , 5 y ago (other than basal
cell or squamous cell carcinoma of skin)
 Participating in other clinical trial that included medication
Note: Inclusion and exclusion criteria as approved by the
medical ethics committee and described in the Netherlands Trial
Registry (study number: NTR2917).
Abbreviations: BP, blood pressure; eGFR, estimated
glomerular filtration rate; RAAS, renin-angiotensin-aldosterone
system.
Meuleman et almultiple barriers when reducing sodium intake,5,6
including insufficient motivation, knowledge, feed-
back, coping skills, and personal goal setting. Hence, to
successfully change lifestyle, theory-based self-
regulation interventions that encompass multiple
behavior change techniques are required.7-11 However,
such self-management interventions to support patients
with CKD to overcome these barriers and incorporate
the sodium guideline into their daily lives are lacking.
Until now, mostly crossover trials have been con-
ducted; these studies have shown that if patients with
CKD adhere to a low-sodium diet, important risk
factors for disease progression can be reduced,12,13
including blood pressure (BP) and protein excre-
tion.14-17 However, these studies did not include
behavioral approaches needed for long-term adher-
ence and only evaluated efficacy directly after rela-
tively brief (2-6 weeks) and strictly regulated
interventions. Hence, they do not provide information
about the effectiveness and sustainability of sodium
interventions to support patients in real-life settings.
To our knowledge, there are only 2 pragmatic trials
that included 24-hour urinary sodium excretion as an
outcome parameter (ie, the gold standard18). First, De
Brito-Ashurst et al19 reduced sodium intake by means
of educational cooking sessions, but only evaluated
effects immediately after the intervention. Second, the
Multifactorial Approach and Superior Treatment Ef-
ficacy in Renal Patients With the Aid of Nurse Prac-
titioners Study (MASTERPLAN) study aimed at strict
implementation of multiple treatment guidelines with
the aid of nurse practitioners, which led to increased
medication adherence, but did not improve lifestyle
adherence.20 Moreover, both interventions lacked a
theoretical basis, were mainly education based, and
included only a few behavior change techniques.
Therefore, we designed a 3-month self-management
intervention based on self-regulation theory,21,22
encompassing various evidence-based behavior change
techniques7-11 to support patients with CKD in reducing
their daily sodium intake. The aim of this Effects of Self-
monitoring on Outcome of Chronic Kidney Disease
(ESMO) trial was to investigate whether the intervention
would result in reduced sodium intake and improved
health outcomes (eg, BP and protein excretion) directly
after the 3-month intervention and at the 6-month follow-
up. In addition, because the literature has shown that
self-management interventions can improve patients’
well-being, this study also aimed to improve health-
related quality of life (HRQoL)23 and self-efficacy
(ie, confidence in ability to manage the disease).24
METHODS
Study Design
This open randomized controlled trial was conducted from
June 2011 to August 2014 at the nephrology departments of 32
university hospitals and 1 general teaching hospital in the
Netherlands: Leiden University Medical Center, University Med-
ical Center Groningen, Academic Medical Center Amsterdam, and
Sint Antonius Hospital Nieuwegein. Written informed consent was
obtained from all participants before inclusion. This study was
approved by the medical ethics committees of all centers
(P10.056) and complies with the Declaration of Helsinki. The
CONSORT (Consolidated Standards of Reporting Trials) checklist
was used as reference for reporting.25
Participants and Randomization
From June 2011 through March 2014, patients with moderately
decreased kidney function and hypertension were recruited (Box 1
depicts all inclusion and exclusion criteria). Eligible patients
received an invitation, information regarding the procedure and
confidentiality, an informed consent form, and a baseline ques-
tionnaire. Upon receiving patients’ written informed consent at the
external data management center (Nefrovisie), a medical infor-
mation specialist allocated patients to the intervention or control
condition using a computer-based block randomization procedure.
The number of patients in each condition was predefined, and
different sizes of blocks were used to prevent too many patients
being consecutively assigned to the same condition. Only the
medical information specialist knew the block sizes. Thereafter,
researchers and patients were notified of the allocation.
Study Protocol
Both groups received regular care according to the Dutch
Federation of Nephrology treatment guidelines1 (based on NKF-
KDOQI [National Kidney Foundation2Kidney Disease Out-
comes Quality Initiative]26 and KDIGO [Kidney Disease:
Improving Global Outcomes] guidelines27). Regular care con-
sisted of consultations with the nephrologist every 3 to 6 monthsAm J Kidney Dis. 2016;-(-):---
Sodium Restriction in CKDand, if necessary, nutrition counseling by a dietician. Those who
received only regular care were the control group.
Patients in the intervention group also received the 3-month self-
management intervention. During the intervention, patients were
coupled with one of 4 personal coaches: 3 health psychologists and 1
dietician, all trained in motivational interviewing techniques.28 The
intervention started with a 1-hour individual motivational interview
at the patient’s hospital, which focused on discussing barriers,
benefits, and strategies for sodium reduction; setting personal so-
dium goals; and strengthening intrinsic motivation and self-efficacy.
Thereafter, patients received education, a kidney-friendly cookbook,
and instructions for self-monitoring BP (using a Microlife WatchBP
Home device), dietary intake (using an online food diary; www.
mijnnierinzicht.nl by Bonstato), and 24-hour urinary sodium
excretion (using an innovative point-of-care chip-device [Medimate
BV]).29 Patients were instructed to take measurements at least once a
week in the first 6 weeks and, depending on patients’ preferences,
thereafter once every 2 or 3 weeks. Following these self-monitoring
measurements (ie, with the same frequency), patients received
feedback by telephone from their coach and discussed progression,
achievements, barriers, and possible solutions. After 3 months, a
final motivational interview took place that focused on evaluation
and relapse prevention. For a detailed intervention description
following theCoventry, Aberdeen and LondonRefined (CALO-RE)
taxonomy of behavior change techniques,30 see Item S1. Finally, if
desired, patients received information regarding social support,
refusal skills, medication adherence strategies, physical exercise,
healthy eating, smoking, and alcohol intake.
Measurements and Outcomes
Data Acquisition
Data were collected at baseline, directly after the 3-month
intervention, and at the 6-month follow-up. Sociodemographic,
anthropometric, and medical data were collected during hospital
visits by individuals not blinded to treatment allocation, using a
secured online Case Report Form. Biochemical data were extrac-
ted from hospital information systems. Psychosocial measures
were acquired using self-report questionnaires. All data were
collected and stored on a secured server under administration of
the data management center.
Primary Outcomes
Sodium intake was estimated from 24-hour urinary sodium
excretion. BP was measured with ambulatory BP monitoring using
validated Spacelabs 90207 and 90217 devices. Monitors were
programmed for 24 hours with 15-minute day intervals and 30-
minute night intervals. Recordings were corrected for patients’
sleep-wake rhythm and considered satisfactory when meeting
criteria of the European Society of Hypertension guidelines.31
Office BP was measured by taking the average of 3 measure-
ments using Microlife WatchBP Home after 5 minutes of rest.
Secondary Outcomes
Because clinicians use different measures for kidney function,
kidney function was measured as creatinine clearance corrected for
body surface area (using the DuBois and DuBois32 formula) and
estimated glomerular filtration rate (using the 4-variable MDRD
[Modification of Diet in Renal Disease] Study equation33). Protein
excretion was measured using 24-hour urinary protein excretion,
and antihypertensive medication use was calculated by taking a
sum score of the number of antihypertensive medications. HRQoL
was assessed with the 36-Item Short Form Health Survey ques-
tionnaire.34 Scores for physical and mental HRQoL ranged from
0 to 100, with higher scores indicating better HRQoL. The ques-
tionnaire showed good reliability, with Cronbach alpha values of
0.92 and 0.82 for physical and mental HRQoL, respectively.Am J Kidney Dis. 2016;-(-):---Furthermore, self-efficacy was assessed by the Chronic Disease
Self-Efficacy Scales2Manage Disease in General Scale.35 Scores
ranged from 1 to 10, with higher scores indicating a stronger belief
in the capability of managing the disease. This questionnaire also
showed good reliability, with a Cronbach alpha value of 0.73. In
addition, because body weight is often reduced after sodium in-
terventions,15,36 body weight was also measured with shoes
removed using the hospitals’ calibrated digital scales.
Power Calculation and Statistical Analysis
To detect a difference of 4 mm Hg in 24-hour systolic BP,37
with an estimated standard deviation of 7 mm Hg,38 a 2-sided
significance of 0.05, and a power of 90%, 64 patients were
needed in each group. Taking into account a dropout rate of 15%,
we aimed to include 150 patients.
Descriptive statistics were computed to describe baseline
characteristics. To investigate the effectiveness of the interven-
tion, we focused on the effect of the study group over time using
intention-to-treat analysis and linear mixed modeling. Assump-
tions for linear mixed modeling were valid for all outcomes.
Models included the following fixed variables: group, time, and
the various continuous dependent variables. Furthermore, models
included patient-level random effects to account for correlation
between patients’ repeated measures over time. An interaction
term was also included as fixed variable: group 3 time point,
which indicated the effect (ie, change in scores for dependent
variables) of the study group by time. To increase the precision of
our estimates, models were adjusted for the baseline value.
Because a linear mixed model takes into account missing out-
comes but not missing covariates, missing baseline values were
imputed using multiple imputation (using 10 repetitions) because
we do not believe “missing not at random” was dominant.39
Several sensitivity analyses were performed to test the robust-
ness of our results (Item S1; including primary analysis adjusted
for baseline covariates, without adjustments, and as-treated




In total, 151 of 333 (45.3%) eligible patients
provided written informed consent. Hereafter, 138
patients started the allocated group and 26 patients
dropped out during the trial, leaving 112 (74.2%)
patients who completed the allocated group. In total,
138 patients were included in the primary intention-
to-treat analysis: 67 patients in the intervention
group and 71 patients in the control group. Figure 1
depicts the participant flow.
Baseline Characteristics
In this sample of 138 patients, mean estimated
glomerular filtration rate was 49.7 6 25.6 (standard
deviation) mL/min/1.73 m2 and median protein
excretion rate was 0.8 (interquartile range, 0.4-1.7)
g/24 h. In addition, mean 24-hour ambulatory systolic
and diastolic BPs were 129 6 15 and 76 6 9 mm Hg,
respectively, and mean sodium excretion rate was
163.6 6 64.9 mmol/24 h (Table 1). Various differ-
ences between the intervention and control groups
were observed (Item S2).3
Eligible for inclusion and received information package (n=333)
Excluded (n=182)
- Practical burden (n=70)
- No interest in study (n=32)
- Poor health/well-being (n=25)
- Other reasons (n=16)
- No reason declared (n=13)








Allocated to control condition (n=76) 
Did not start allocated condition (n=5)
- Health problems (n=5)
Withdrawn from study (n=13)
- Too much burden and no gain (n=6)  
- Health problems (n=2)
- Too busy (n=2)
- Negative experience phlebotomy (n=1)
- Lost interest (n=1)
- No response (n=1)
Lost in follow-up (n=3)
- Health problems (n=2)
- Car accident (n=1)
Withdraw from study (n=4)
- Healthproblems (n=1)
- Deceased (n=1)
- Too busy (n=1)
- Lost interest (1)
Lost at T1 but re-included at T2 (n=3)
Analyzed at T0 (n=71)
Analyzed at T1 (n=55)
Analyzed at T2 (n=54)  
Analyzed in intention to treat (n=71)
Allocated to intervention condition (n=75) 
Did not start allocated condition (n=8)
- Too busy (n=3)
- Health problems (n=2)
- Language barrier (n=1)
- Deceased (n=1)
- No response (n=1)
Withdrawn from study (n=8)
- Health problems (n=4)
- Too busy (n=1)
- Too much burden (n=1)
- Participation other study (n=1)
- Problems sodium measurement device (n=1) 
Withdraw from study (n=1) 
- Health problems (n=1)
Analyzed at T0 (n=67)
Analyzed at T1 (n=59)
Analyzed at T2 (n=58)
Analyzed in intention to treat (n=67)
Figure 1. Participant flow.
Meuleman et alPatient Adherence, Goals, and Evaluation
In total, 55 patients (82.1%) received the inter-
vention according to protocol. Four (6%) patients did
not attend the final interview, and 8 (12%) patients
did not attend the final interview and had fewer than 5
self-monitoring moments and consultations.
In addition to setting personal sodium goals, 21
(31%) patients set weight-loss goals, 9 (13%) patients
set exercise goals, 1 (2%) patient set a goal to reduce
alcohol intake, and 3 (5%) patients wanted to receive
information regarding medication adherence strate-
gies, social support, or refusal skills.4
Patient satisfaction with the intervention was high:
42 (63%) patients returned the evaluation question-
naire and gave the intervention a mean score of
7.96 0.9 on a 10-point scale, with higher scores
indicating greater satisfaction. All separate interven-
tion components (ie, education, motivational in-
terviews, feedback consultations, and self-monitoring
tools) were evaluated as very useful: mean scores
ranged from 4.06 0.7 to 4.7 6 0.6 on a 5-point scale,
with higher scores indicating greater usefulness. It is
important to note that although the food diary and
sodium measurement device were evaluated as veryAm J Kidney Dis. 2016;-(-):---
Table 1. Baseline Patient Characteristics
Characteristic Intervention (n 5 67) Control (n 5 71)
Age, y 55.6 6 11.7 54.7 6 16.0
Male sex 53 (79) 60 (85)
Dutch ethnicity 59 (88) 66 (93)
Married or cohabiting 59 (88) 53 (75)
Low education 40 (60) 48 (68)
Paid job 37 (55) 35 (49)
Primary cause of kidney failurea
Diabetes mellitus 6 (9) 2 (3)
Glomerulonephritis 16 (24) 14 (20)
Renal vascular disease 16 (24) 21 (30)
Other cause 29 (43) 34 (48)
Diabetes mellitus 20 (30) 15 (21)
Cardiovascular diseaseb 24 (36) 28 (39)
Kidney transplant recipientc 17 (25) 10 (14)
Sodium excretion rate, mmol/24 hd 151.16 66.9 176.16 60.9
Sodium-creatinine ratio, mmol/g (24 h)e 103.76 44.4 114.76 40.9
Protein excretion rate, g/24 hf 0.70 [0.33-1.33] 0.91 [0.41-2.16]
eGFR, mL/min/1.73 m2g 47.6 6 25.0 51.8 6 26.2
BSA-corrected CLcr, mL/min/1.73 m
2h 46.0 [32.3-69.3] 55.1 [40.1-81.8]
Potassium excretion rate, mmol/24 hi 69.8 6 21.5 73.5 6 28.1
Hemoglobin, g/dLj 14.1 6 1.9 13.76 1.5
Total cholesterol, mg/dLl 197.26 42.5 193.36 38.7
24-hour SBP, mm Hgk,m 1296 15 1286 15
24-hour DBP, mm Hgk,m 77 6 10 75 6 9
Office SBP, mm Hg 1426 19 1376 17
Office DBP, mm Hg 87 6 11 83 6 10
Body weight, kg 90.9 6 15.7 92.7 6 16.9
Body mass index, kg/m2 29.7 6 5.4 29.76 5.2
HRQoL–Physicaln 70.8 6 21.1 65.2 6 24.3
HRQoL–Mentalo 73.9 6 19.5 72.0 6 18.1
Self-efficacyp 7.56 1.3 7.9 6 0.9
Anti-HTN medication use 64 (96) 70 (99)
Sum score anti-HTN medication 2.3 (1.2) 2.4 (1.1)
RAAS blockade use 50 (75) 60 (85)
ARBs 27 (40) 27 (38)
ACE inhibitors 27 (40) 37 (52)
Calcium channel blocker use 26 (39) 29 (41)
b-Blocker use 28 (42) 30 (42)
Diuretic use 30 (45) 35 (49)
a1-Adrenergic blocker use 8 (12) 3 (4)
Other anti-HTN medication use 8 (12) 2 (3)
Note: Values for categorical variables are given as count (proportion); values for continuous variables are given as mean6 standard
deviation for normally distributed variables or median [interquartile range] for skewed variables. Conversion factor for cholesterol in
mg/dL to mmol/L, 30.02586. Low education was classified as: primary education and lower secondary education.
Abbreviations: ACE, angiotensin-converting enzyme; ABPM, ambulatory blood pressure monitoring; ARBs, angiotensin II type 1
receptor antagonists; BSA, body surface area; CLcr, creatinine clearance; DBP, diastolic blood pressure; eGFR, estimated glomerular
filtration rate; HRQoL, health-related quality of life; HTN, hypertension; RAAS, renin-angiotensin-aldosterone system; SBP, systolic
blood pressure.
aPrimary kidney disease was classified into 4 categories according to European Renal Association/European Dialysis and Trans-
plant Association codes.50
bCardiovascular disease was defined by the presence of angina pectoris, coronary disease, and/or myocardial infarction.
cTo meet inclusion criteria, transplantation had to have occurred .1 year prior to inclusion.
Complete data available with the exception of the following variables, with data available for: d66 intervention patients (99%) and 66
control patients (93%), e65 intervention patients (97%) and 66 control patients (93%), f63 intervention patients (94%) and 66 control
patients (93%), g64 control patients (90.1%), h65 intervention patients (97.0%) and 62 control patients (87.3%), i66 intervention pa-
tients (99%) and 65 control patients (92%), j65 control patients (92%), l64 control patients (90%), m58 intervention patients (87%) and
55 control patients (78%), n63 intervention patients (94%) and 70 control patients (99%), o63 intervention patients (94%) and 69 control
patients (97%), and p64 intervention patients (96%) and 69 control patients (97%).
kA total of 133 complete ABPM measurements were available: 66 in the intervention group (99%) and 67 in the control group (94%).
Following the guidelines for reliable ABPM measurements, recordings were blind evaluated and 20 ABPM measurements (15%) were
excluded from analyses (8 [12%] in the intervention group and 12 [18%] in the control group).
Am J Kidney Dis. 2016;-(-):--- 5
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Meuleman et aluseful, patients also had some frustration (both mean
scores were 2.36 1.5 on a 5-point scale [higher
scores indicate higher levels of frustration]), which
referred to the complexity of completing the food
diary and to failures of the sodium measurement de-
vice (which meant that the procedure had to be
repeated and, in a few cases, 24-hour urine had to be
collected again or the device had to be replaced).
Primary and Secondary Outcomes
At 3 Months
Several significant differences were observed at the
end of the intervention (Table 2). Compared to regular
care alone, the intervention resulted in a 230.3 (95%
confidence interval [CI], 254.7 to 25.9) mmol/24 h
mean change in sodium excretion rate, 23.4 (95%
CI, 26.3 to 20.6) mm Hg mean change in daytime
diastolic BP, 25.2 (95% CI, 28.4 to 22.1) mm Hg
mean change in diastolic office BP, and 20.4 (95%
CI, 20.7 to 20.1) g/24 h mean change in protein
excretion rate. Furthermore, there was a 0.5 (95% CI,
0.1-0.9) mean increase in self-efficacy score in the
intervention group compared to the control group. No
significant differences between groupswere detected in
antihypertensive medication, kidney function, and
HRQoL. In addition, the intervention group had a
reduction in bodyweight compared to the control group
(mean change,21.5 [95% CI, 22.7 to 20.3] kg).
At 6 Months
No significant differences in sodium excretion and
ambulatory BP measurements were found at the 6-
month follow-up, but several other differences were
observed (Table 2). Compared to regular care only,
the intervention resulted in 27.3 (95% CI, 212.7
to 21.9) and 23.8 (95% CI, 26.9 to 20.6) mm Hg
mean changes in systolic and diastolic office BPs,
respectively, and a mean change of 20.3 (95%
CI, 20.6 to 20.1) g/24 h in protein excretion rate.
There was a 0.5 (95% CI, 0.0-0.9) mean increase in
self-efficacy score in the intervention group compared
to the control group. No significant differences be-
tween groups were detected in antihypertensive
medication, kidney function, and HRQoL. In addi-
tion, there was a reduction in body weight in the
intervention group compared to the control group
(mean change, 21.7 [95% CI, 22.9 to 20.5] kg).
All within- and between-group effects are shown in
Table 2, Fig 2 (sodium excretion, protein excretion,
and systolic and diastolic 24-hour BPs), and Fig S1
(all other outcomes).
Finally, sensitivity analysis showed that most re-
sults remained stable, including the analysis adjusted
for baseline covariates, the analysis without adjust-
ments, and as-treated analysis (Item S2).6
DISCUSSION
To our knowledge, ESMO is the first study to
investigate whether sodium intake in patients with
CKD can be changed by means of a theory-based self-
management intervention and to evaluate not only the
effectiveness, but also the sustainability of this real-
life intervention. Results indicate that compared to
regular care only, this behavioral approach can
modestly decrease risk factors for disease progression
in patients with CKD. However, effects on the pri-
mary outcomes—sodium excretion and ambulatory
BP—following the intervention diminish over time.
The findings of this study are partly in agreement
with previous research. In contrast to the
MASTERPLAN study,20 but in accordance with the
study of de Brito-Ashurst et al,19 we found that
sodium intake in patients with CKD can be modified
by means of a self-management intervention.
Compared to the intervention effect of De Brito-
Ashurst et al19 of 103 mmol/24 h, our reduction of
30 mmol could be considered modest. Compared to
the Trials of Hypertension Prevention (TOHP) II
study, which evaluated a multifactorial sodium inter-
vention in overweight nonhypertensive adults and
found sodium reductions of 44 and 38 mmol/24 h,40
our sodium reduction could be considered similar
but was not maintained for 6 months. Possible
explanations for the discrepancies can be found in the
intervention design.
First, our intervention was a low intensity interven-
tion compared to the 3-year TOHP II intervention
comprising more than 15 contact moments.40,41
Although evidence for intensity as a moderator for
effectiveness of lifestyle interventions is inconclusive
(eg, Greaves et al11 found intensity to be a moderator,
but Janssen et al42 did not), increased intervention
intensity might have resulted in maintaining the
low-sodium diet. Second, our intervention could be
regarded as an individual-oriented intervention
compared to theDeBrito-Ashurst et al19 andTOHP II40
interventions, which comprised group meetings.
Planning social support was part of our intervention
and significant others were invited to attend meetings.
However, only 23 (34%) patients brought significant
others, and social support among fellow-patients
was not facilitated. Given that social support is asso-
ciated with lifestyle adherence,11,43 increased social
support might have led to stronger effects. Third,
the intervention of De Brito-Ashurst et al19
included cooking lessons, whereas ESMO partici-
pants received a kidney-friendly cookbook. Perhaps
including low-sodium cooking sessions instead of
merely providing written instructions could have
resulted in larger sodium reductions. Finally, the TOHP
II intervention included an extended phase usingAm J Kidney Dis. 2016;-(-):---
Table 2. Intention-to-Treat Analysis Adjusted for Baseline Value
Mean 6 Standard Error of Mean
Effect Intervention (95% CI)Intervention Group Control Group
T0 T1 T2 T0 T1 T2 DT0-T1 DT0-T2
Sodium
Sodium excretion rate, mmol/24 h 159.46 6.0 138.3 6 6.5a 157.06 6.4 167.7 6 6.0 176.96 6.6 162.56 6.8 230.3 (254.7 to 25.9)b 2.9 (221.6 to 27.3)
Blood pressure
24-hour SBP, mm Hg 1296 1.1 125 6 1.2a 1286 1.2 128 6 1.1 1276 1.2 1306 1.2 22.2 (26.4 to 1.9) 22.1 (26.3 to 2.1)
24-hour DBP, mm Hg 76 6 0.7 74 6 0.8a 75 6 0.8 76 6 0.7 76 6 0.8 77 6 0.8 22.4 (25.1 to 0.3) 22.2 (24.9 to 0.5)
Day SBP, mm Hg 1326 1.1 128 6 1.3c 1316 1.3 132 6 1.2 1316 1.3 1336 1.3 22.9 (27.2 to 1.4) 21.9 (26.3 to 2.4)
Day DBP, mm Hg 80 6 0.7 77 6 0.8c 78 6 0.8 79 6 0.8 80 6 0.9 80 6 0.9 23.4 (26.3 to 20.6)b 22.3 (25.2 to 0.5)
Night SBP, mm Hg 1206 1.2 1176 1.4 1206 1.4 120 6 1.3 1206 1.4 1216 1.4 22.5 (27.3 to 2.2) 21.8 (26.6 to 3.0)
Night DBP, mm Hg 69 6 0.8 68 6 0.9 69 6 0.9 69 6 0.9 69 6 0.9 70 6 1.0 20.9 (24.0 to 2.2) 21.2 (24.3 to 1.9)
Office SBP, mm Hg 1406 1.5 134 6 1.5c 133 6 1.6c 138 6 1.4 1356 1.6 1396 1.6 22.9 (28.3 to 2.4) 27.3 (212.7 to 21.9)d
Office DBP, mm Hg 85 6 0.9 80 6 0.9c 81 6 0.9c 84 6 0.8 84 6 0.9 83 6 0.9 25.2 (28.4 to 22.1)d 23.8 (26.9 to 20.6)b
Clinical
Protein excretion rate, g/24 h 1.26 0.1 1.06 0.1 1.16 0.1 1.2 6 0.1 1.4 6 0.2a 1.4 6 0.1a 20.4 (20.7 to 20.1)d 20.3 (20.6 to 20.1)b
eGFR, mL/min/1.73 m2 49.9 6 1.1 49.4 6 1.1 49.6 6 1.1 49.5 6 1.1 49.3 6 1.2 46.9 6 1.2c 20.3 (22.9 to 2.3) 2.3 (20.4 to 4.9)
BSA-corrected CLcr, mL/min/1.73 m
2 59.0 6 2.2 60.7 6 2.3 58.8 6 2.3 59.0 6 2.2 62.8 6 2.4 59.8 6 2.4 22.2 (29.8 to 5.4) 21.0 (28.7 to 6.7)
Total no. of anti-HTN medications 2.36 0.2 2.36 0.2 2.36 0.2 2.3 6 0.2 2.36 0.2 2.36 0.2 20.0 (20.3 to 0.2) 20.0 (20.3 to 0.2)
Body weight, kg 91.4 6 0.3 89.9 6 0.4c 89.8 6 0.4c 91.4 6 0.3 91.4 6 0.4 91.5 6 0.4 21.5 (22.7 to 20.3)b 21.7 (22.9 to 20.5)d
Psychosocial
HRQoL–Physical 68.9 6 1.7 69.3 6 1.8 65.4 6 1.8 67.5 6 1.6 65.4 6 1.8 66.4 6 1.9 2.4 (23.3 to 8.2) 22.4 (28.2 to 3.3)
HRQoL–Mental 73.7 6 1.5 75.8 6 1.6 75.2 6 1.6 72.9 6 1.4 72.7 6 1.6 74.9 6 1.7 2.3 (23.1 to 7.7) 20.5 (25.9 to 4.9)
Self-efficacy 7.66 0.1 8.1 6 0.1c 7.96 0.1 7.8 6 0.1 7.86 0.1 7.66 0.1 0.5 (0.1 to 0.9)b 0.5 (0.0 to 0.9)b
Note: n5 138.
Abbreviations: BSA, body surface area; CI, confidence interval; CLcr, creatinine clearance; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; HRQoL, health-related
quality of life; HTN, hypertension; SBP, systolic blood pressure; T0, baseline; T1, 3 months’ follow-up; T2, 6 months’ follow-up.
aP , 0.05; mean (standard error of mean) differs significantly from baseline.
bP , 0.05; change in mean over time (95% CI) differs significantly from control group.
cP , 0.01; mean (standard error of mean) differs significantly from baseline.




































Figure 2. Within- and between-group effects of primary intention-to-treat analyses adjusted for baseline value: (A) sodium excre-
tion, (B) protein excretion, (C) 24-hour systolic blood pressure (SBP), and (D) 24-hour diastolic blood pressure (DBP). *P , 0.05,
**P, 0.01; mean (standard error of mean) differs significantly from baseline. yP, 0.05, yyP , 0.01; change in mean over time
(95% confidence interval) differs significantly from control group. Abbreviations: T0, baseline; T1, 3 months’ follow-up; T2, 6 months’
follow-up.
Meuleman et alfollow-up prompts.41 In our study, contact frequency
was gradually reduced, but follow-up prompts (eg,
postcards or booster sessions) were not included.
Follow-up prompts have been associated with
increased effectivity10; therefore, including an
extended phase could have resulted in maintaining the
low-sodium diet.
Similar to the literature,3,16,17,19 our sodium inter-
vention also reduced BP. However, our ambulatory
BP reductions did not remain significant at the 6-
month follow-up time and could be considered
modest compared to the 8/2 mm Hg reduction in 24-
hour BP by the self-management intervention of De
Brito-Ashurst et al19 and the reduction of 9/4 mm Hg
(combining 24-hour and office measures) found by a
recent meta-analysis.3 Discrepancies could be
explained by study design (ie, the meta-analysis
included many crossover studies and effectiveness
was only measured directly after interventions) and
the larger sodium intervention effects ofw100 mmol/
24 h found in these studies.3,19
In accordance with previous crossover studies,14-17
results showed that our intervention reduced protein
excretion, but our effects (reductions of 0.4 and
0.3 g/24 h at 3 and 6 months) seem small compared to
the reduction of 0.8 g/24 h found by Vogt et al,15 for
example. However, the baseline protein excretion rate
in our group was low compared to that in Vogt et al
(ie, 1.2 vs 3.8 g/24 h), and hence the percentage
decrease in protein excretion could be considered
comparable.8
Furthermore, the literature suggests that reducing
sodium intake could have beneficial effects on CKD
progression.12,13 However, our study was underpow-
ered to detect differences in kidney function and our
follow-up was too short to confirm long-term bene-
ficial effects. In line with this, no significant group
differences were detected, although estimated
glomerular filtration rates decreased in the control
group.
In accordance with the literature,24 this intervention
also increased patients’ beliefs that they are capable of
managing their kidney disease. However, contrary to
Campbell et al,23 our intervention did not improve
HRQoL. This discrepancy might be explained by
patient characteristics; whereas Campbell et al
included non–dialysis-dependent patients with
advanced CKD with impaired HRQoL, we included
patients with moderately decreased kidney function
and relatively high HRQoL.
Finally, although not specified in the original
protocol, a reduction in body weight was also
observed in the intervention group. This finding cor-
responds partially with the literature; previous studies
found decreased body weight after sodium in-
terventions,15,36 but significant body weight re-
ductions have not been found in the study by De
Brito-Ashurst et al19 and a recent meta-analysis.3
An explanation for our intervention effect could be
that the weight reduction was not sodium specific, but
due to weight loss goals that 21 (31%) participants set
in addition to sodium goals. Unfortunately, objectiveAm J Kidney Dis. 2016;-(-):---
Sodium Restriction in CKDmarkers of body composition were not collected to
attribute this reduced body weight to either changes in
body fat or fluid status.
Specific strengths of this study include a tailored
intervention according to the needs of patients and
health care professionals as assessed in a preparatory
qualitative study5 and the application of multiple
evidence-based behavior change techniques.7-11
Furthermore, because self-monitoring is a compo-
nent of effective lifestyle interventions9,42 and pa-
tients with CKD have stressed the need for additional
feedback regarding sodium,5 the inclusion of 2 so-
dium self-monitoring tools (ie, online diary and so-
dium measurement device) could be seen as a
strength. However, patients also encountered prob-
lems with these self-monitoring tools, which might
have hampered the effectiveness of this intervention
(eg, negative feelings or less sodium feedback).
Therefore, the inclusion of these self-monitoring tools
could also be considered a study limitation. Another
limitation is nonblinding; due to the active nature of
the intervention, concealment of randomization was
not possible. In addition, it is possible that trial
participation and active recruitment caused both
groups to reduce their sodium intakes prior to baseline
measurements. This potential Hawthorne effect44
might have contributed to the modest effects found.
Furthermore, this study has missing data that could
possibly lead to biases. However, because clinical
trials often deal with missing data, we performed
intention-to-treat analyses to avoid overestimating
intervention effects.45 To avoid biased estimates and
loss of power, we also used linear mixed modeling
and performed analyses while adjusting for imputed
missing baseline values (1.7% in the intervention
group and 3.8% in the control group).39 Our response
rate could also be considered relatively low and hence
limits generalization of results. However, similar
response rates have been found in previous self-
management interventions (eg, 47% by Bucknall
et al46). Finally, we included a heterogeneous group
including patients who might have different renal
responses to sodium restriction. However, recent
studies have shown that sodium restriction also
effectively reduced BP in patients who had received
transplants47 and in patients with type 2 diabetic ne-
phropathy.48 Moreover, inclusion of different patient
groups could be considered a strength as well because
patients under nephrologic care represent a highly
heterogeneous group, and hence increases the gener-
alizability of our results.
With this study, we report a small but important
step to support patients with CKD in reducing sodium
intake. However, additional research is needed to
provide further insight into the intervention effects,
for instance, the change in (amounts of) high- orAm J Kidney Dis. 2016;-(-):---low-sodium food products by means of food diary
data. Furthermore, given that self-efficacy is associ-
ated with self-care behaviors,43,49 additional research
is needed to investigate the mediating role of self-
efficacy. Finally, future studies should also investi-
gate whether the ESMO intervention effects could be
improved by including a more robust and user-
friendly sodium measurement device and a less
complex online food diary, intensifying the inter-
vention, involving patients’ social environment, and
adding booster sessions.
In conclusion, compared to regular care alone, this
theory-based sodium self-management intervention
modestly improved risk factors for disease progres-
sion in patients with CKD, although effects on so-
dium and ambulatory BP following the intervention
diminished over time.
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